К вопросу о применении дабигатрана при персистирующей фибрилляции предсердий

The article highlights the prevention of thromboembolic events in patients with atrial fibrillation. The clinical case is presented and focused on direct thrombin inhibitor dabigatran administration as a secondary prevention strategy of thromboembolism (of an arrhythmogenic origin)